SCM
FLNA

Stonepine Capital Management’s Filana Therapeutics FLNA Stock Holding History

Stonepine Capital Management’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-405,411
Closed -$6.21M – 19
2016
Q2 		$6.21M Sell
405,411
-98,932
-20% -$1.57M 6.37% 6
2016
Q1 		$7.87M Sell
504,343
-6,371
-1% -$82.4K 9.28% 4
2015
Q4 		$6.26M Buy
+510,714
New +$6.76M 7.33% 7

Other funds holding FLNA

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Stonepine Capital Management's FLNA Position: Q3 2016 in Review

Stonepine Capital Management sold out of Filana Therapeutics (FLNA) in Q3 2016, closing a stake of 405,411 shares — an estimated $6.21M sold.

Stonepine Capital Management first reported a position in FLNA in Q4 2015 and held it in 3 quarters. The position peaked at $7.87M in Q1 2016. 48 funds tracked by Wall St. Rank hold FLNA as of Q3 2016.

  • Stonepine Capital Management reported no remaining Filana Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Stonepine Capital Management sold 405,411 Filana Therapeutics shares in Q3 2016, an estimated $6.21M.
  • Stonepine Capital Management first reported a position in Filana Therapeutics in Q4 2015 and held it in 3 quarters.
  • Stonepine Capital Management's Filana Therapeutics position peaked at $7.87M in Q1 2016.
  • 48 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2016.

Based on Stonepine Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.